Changes in Anxiety Severity and Acceptability of Venlafaxine in Generalized Anxiety Disorder in the United States: Results From a Real-World Study

Christoph U Correll,1– 5 Kannan Subramaniam,6 Pradeep Purushottamahanti,7 Bituparna Bayan,8 Luke A Bryden,9 Emily OC Palmer,9 Nadia Lipunova91Department of Psychiatry, Zucker Hillside Hospital, Northwell Health, Glen Oaks, NY, USA; 2Department of Psychiatry and Molecular Medicine, Zucker School of M...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Correll CU, Subramaniam K, Purushottamahanti P, Bayan B, Bryden LA, Palmer EOC, Lipunova N
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Dove Medical Press 2026-07-01
Rangatū:	Neuropsychiatric Disease and Treatment
Ngā marau:	all-cause discontinuation anxiety disorders effectiveness real-world evidence serotonin and noradrenaline reuptake inhibitor
Urunga tuihono:	https://www.dovepress.com/changes-in-anxiety-severity-and-acceptability-of-venlafaxine-in-genera-peer-reviewed-fulltext-article-NDT
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!